Lupus & antiphospholipid syndrome
Diagnostic performance of anti-DFS70 antibodies in excluding systemic lupus erythematosus diagnosis: An updated systematic review and meta-analysis
Authors' conclusion
While the present study corroborates findings that the frequency of anti-DFS70 antibodies is slightly higher in SLE patients (10.1%, 244 out of 2427), the lack of statistical significance underscores the need for more comprehensive studies to draw definitive conclusions for the exclusion of SLE.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) and healthy individuals; utility of anti-DFS70 antibodies in excluding SLE in the general population
- Participants
- 6,092 patients16 studies
- Comparison
- Anti-DFS70 antibodies in SLE patients vs healthy individuals
- SLEn = 2,427
- Healthy individuals (HI)n = 3,665reference
- Outcome
- Sensitivity, specificity and diagnostic odds ratio (DOR) of anti-DFS70 antibodies for excluding SLE
Methodological detailsupdated
- Updated
Pooled result
As reported in the abstract
Pooled sensitivity
0.10
95% CI 0.09–0.11
Pooled specificity
0.94
95% CI 0.93–0.95
Pooled diagnostic odds ratio (DOR)
1.04
95% CI 0.59–1.85
Area under summary receiver operating characteristic (SROC) curve (95% CI 0.28-0.90); test results have similar distributions in SLE and HI
0.58
Further pooled results
Monospecific anti-DFS70 antibodies (3 studies; 385 SLE, 648 HI)
| Outcome | SLE | HI |
|---|---|---|
| Prevalence of anti-DFS70 antibodies | 10.1% (95% CI 5.7–14.5%) | 5.8% (95% CI 2.9–8.7%) |
- Monospecific anti-DFS70 antibodies (3 studies; 385 SLE, 648 HI) — DOR for excluding SLE diagnosis
- 4.00 (95% CI 1.39-11.46)
Prevalence of anti-DFS70 antibodies
- Not significantly higher in SLE than HI
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →